| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 7.976 | 7.470 | 14.566 | 16.971 | 5.820 | 10.057 | 22.780 | 38.062 | 17.713 |
| Total Income - EUR | - | 7.976 | 7.573 | 14.954 | 17.400 | 6.211 | 10.704 | 23.419 | 38.434 | 18.629 |
| Total Expenses - EUR | - | 1.728 | 845 | 1.083 | 1.335 | 1.851 | 1.460 | 1.157 | 2.770 | 1.949 |
| Gross Profit/Loss - EUR | - | 6.248 | 6.728 | 13.871 | 16.065 | 4.360 | 9.244 | 22.262 | 35.664 | 16.680 |
| Net Profit/Loss - EUR | - | 6.009 | 6.503 | 13.428 | 15.550 | 4.166 | 8.958 | 21.670 | 30.814 | 14.411 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Polixenia Iorga Oncotrial Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.339 | 813 |
| Current Assets | - | 6.951 | 13.255 | 26.181 | 41.240 | 42.582 | 51.216 | 73.169 | 104.125 | 117.958 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 302 | 297 | 2.774 | 6.628 | 2.080 | 3.872 | 7.709 | 5.067 | 1.049 |
| Cash | - | 6.649 | 12.958 | 23.406 | 34.612 | 40.502 | 47.344 | 65.460 | 99.059 | 116.910 |
| Shareholders Funds | - | 6.053 | 6.556 | 19.863 | 35.028 | 36.495 | 44.643 | 66.451 | 97.064 | 110.933 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 897 | 6.699 | 6.317 | 6.310 | 6.126 | 6.573 | 6.718 | 8.401 | 7.838 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Polixenia Iorga Oncotrial Srl